Market cap data unavailable. We couldn't positively verify this ticker's market cap is under $500M. Verify independently before trading.
Curative Biotechnology, Inc.
- Market Cap
- Unavailable
- Price
- $1.25
- % Change (Daily % change from the live per-ticker quote feed.)
- +35.87%
- Volume
- 5.1K
About
Curative Biotechnology, Inc. is an emerging biomedical firm primarily focused on developing pharmaceutical products. Its research and development efforts are concentrated on a diverse pipeline targeting critical therapeutic areas, including infectious diseases, cancer, and vision-impairing degenerative eye conditions. Among its key pipeline assets is IMT504, an innovative immunotherapy designed for rabies treatment and as a vaccine enhancer. Another prominent candidate is CUBT906, a fully humanized CD56 monoclonal antibody that delivers a pyrrolobenzodiazepine dimer directly to tumor cells, aiming to eradicate them by halting their growth and spread. Additionally, the company is advancing a reformulated Metformin for the management of degenerative eye disorders. Curative Biotechnology has entered into a licensing and co-development partnership with Mid-Atlantic BioTherapeutics, Inc. to further advance IMT504, specifically for addressing advanced rabies and as a component of a COVID-19 vaccine. Previously known as Connectyx Technologies Holdings Group, Inc., the company adopted its current name, Curative Biotechnology, Inc., in November 2020. Established in 1995, the company maintains its headquarters in Boca Raton, Florida.
Quick stats
Shares outstanding—
Computed float1.4M
Float / sharesUnknown
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001400271
Websitehttps://curativebiotech.com
AI Summary
AI-generated1/3
minorneutraloperations update
Curative Biotechnology, Inc. Issues Letter to Shareholders
Curative Biotechnology (OTC: CUBT) issued a shareholder letter reviewing a year of progress on its metformin-based topical ophthalmology platform for degenerative retinal diseases, led by its program in intermediate- and late-stage Age-Related Macular Degeneration.
On intellectual property, the Canadian IP Office (January) and the USPTO (July) issued Notices of Allowance covering topical metformin methods for retinal degeneration, including AMD and Stargardt's disease; Curative is the exclusive worldwide licensee of the underlying technology from the National Eye Institute.
Operationally, a Sponsored Research Agreement signed with PennVet in May is testing the formulation in a canine model of retinal degeneration, and the company has commenced cGMP manufacturing of clinical supply for a planned first-in-human AMD study to be run by the NEI under a CRADA.
The letter also confirms the March 2026 completion of a 1-for-150 reverse split that cut roughly 1.02 billion shares to about 6.8 million, with management still evaluating ways to strengthen the capital position and pursue strategic and institutional investors to fund development.
Red flags
- 1-for-150 reverse split completed in March 2026 — extreme ratio signals severe prior dilution and public-market positioning pressure
- Pre-split share count of ~1.02 billion shares reflects a heavy dilution history for this OTC micro-cap
- Development-stage, pre-revenue company explicitly still 'pursuing the capital and strategic relationships necessary' to advance programs
- USA TODAY mention is 'Contributor Content' (paid placement), not independent editorial coverage